ProSE™ Platform Development

About Glyphic Biotechnologies

Glyphic Biotechnologies is an early-stage innovator targeting the transformative opportunity in proteomics with its proprietary ProSE™ technology. The platform employs a three-step process of peptide functionalization, molecular expansion to space out amino acids, and nanopore-based sequencing to read single-amino-acid signatures. Positioned as a pre-revenue platform company, Glyphic is building its team and technology with a target milestone around 2026, aiming to address the critical gap between genomic information and functional protein biology for research and future diagnostic/therapeutic applications.